WO2017025944A3 - Macrophage chimeric antigen receptor (moto-car) in imunotherapy - Google Patents

Macrophage chimeric antigen receptor (moto-car) in imunotherapy Download PDF

Info

Publication number
WO2017025944A3
WO2017025944A3 PCT/IB2016/056140 IB2016056140W WO2017025944A3 WO 2017025944 A3 WO2017025944 A3 WO 2017025944A3 IB 2016056140 W IB2016056140 W IB 2016056140W WO 2017025944 A3 WO2017025944 A3 WO 2017025944A3
Authority
WO
WIPO (PCT)
Prior art keywords
car
chimeric antigen
imunotherapy
moto
macrophage
Prior art date
Application number
PCT/IB2016/056140
Other languages
French (fr)
Other versions
WO2017025944A2 (en
Inventor
Kim O'NEILL
Scott Weber
Original Assignee
Brigham Young University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2998406A priority Critical patent/CA2998406A1/en
Priority to KR1020187007097A priority patent/KR20180054600A/en
Priority to EA201890489A priority patent/EA201890489A1/en
Priority to AU2016305353A priority patent/AU2016305353B2/en
Priority to EP16801306.8A priority patent/EP3334764A2/en
Priority to PCT/IB2016/056140 priority patent/WO2017025944A2/en
Application filed by Brigham Young University filed Critical Brigham Young University
Priority to CN201680059778.7A priority patent/CN108137704A/en
Priority to US15/358,395 priority patent/US11352439B2/en
Publication of WO2017025944A2 publication Critical patent/WO2017025944A2/en
Publication of WO2017025944A3 publication Critical patent/WO2017025944A3/en
Priority to ZA2018/01636A priority patent/ZA201801636B/en
Priority to US17/833,149 priority patent/US20220372170A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Modified macrophage immune cells are provided for treatment of cancer and other diseases. In particular said macrophages express chimeric antigen receptors (CAR). The single chain variable fragment (scFv) may be directed against thymidine kinase 1 (TK1)or hypoxanthine guanine phosphoribosyltransferase (HPRT). The signaling domain may be derived from a Toll-like receptor (TLR).
PCT/IB2016/056140 2015-08-13 2016-10-13 Macrophage car (moto-car) in imunotherapy WO2017025944A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020187007097A KR20180054600A (en) 2015-10-13 2016-10-13 The macrophage chimeric antigen receptor (MOTO-CAR)
EA201890489A EA201890489A1 (en) 2015-08-13 2016-10-13 CAR MACROPHAGES (MOTO-CAR) IN IMMUNOTHERAPY
AU2016305353A AU2016305353B2 (en) 2015-08-13 2016-10-13 Macrophage chimeric antigen receptor (MOTO-CAR) in imunotherapy
EP16801306.8A EP3334764A2 (en) 2015-10-13 2016-10-13 Macrophage chimeric antigen receptor (moto-car) in imunotherapy
PCT/IB2016/056140 WO2017025944A2 (en) 2015-08-13 2016-10-13 Macrophage car (moto-car) in imunotherapy
CA2998406A CA2998406A1 (en) 2015-08-13 2016-10-13 Macrophage car (moto-car) in immunotherapy
CN201680059778.7A CN108137704A (en) 2015-10-13 2016-10-13 Macrophage CAR in immunotherapy（MOTO-CAR）
US15/358,395 US11352439B2 (en) 2015-08-13 2016-11-22 Macrophage CAR (MOTO-CAR) in immunotherapy
ZA2018/01636A ZA201801636B (en) 2015-08-13 2018-03-09 Macrophage chimeric antigen receptor (moto-car) in imunotherapy
US17/833,149 US20220372170A1 (en) 2015-08-13 2022-06-06 Macrophage CAR (MOTO-CAR) In Immunotherapy

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62/204,935 2015-08-13
US201562240528P 2015-10-13 2015-10-13
US62/240,528 2015-10-13
US201615236421A 2016-08-13 2016-08-13
US15/236,421 2016-08-13
PCT/IB2016/056140 WO2017025944A2 (en) 2015-08-13 2016-10-13 Macrophage car (moto-car) in imunotherapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US201615236421A Continuation-In-Part 2015-08-13 2016-08-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US201615236421A Continuation 2015-08-13 2016-08-13
US15/358,395 Continuation US11352439B2 (en) 2015-08-13 2016-11-22 Macrophage CAR (MOTO-CAR) in immunotherapy

Publications (2)

Publication Number Publication Date
WO2017025944A2 WO2017025944A2 (en) 2017-02-16
WO2017025944A3 true WO2017025944A3 (en) 2017-04-27

Family

ID=62299116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/056140 WO2017025944A2 (en) 2015-08-13 2016-10-13 Macrophage car (moto-car) in imunotherapy

Country Status (4)

Country Link
EP (1) EP3334764A2 (en)
KR (1) KR20180054600A (en)
CN (1) CN108137704A (en)
WO (1) WO2017025944A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030938B2 (en) 2023-01-20 2024-07-09 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
EP3328402A4 (en) 2015-07-28 2019-04-03 The Trustees Of The University Of Pennsylvania Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
CA3035080A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
CN110662553A (en) * 2017-05-17 2020-01-07 迅雷生物科技有限公司 Transgenic macrophages, chimeric antigen receptors and related methods
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
JP2021529552A (en) * 2018-07-19 2021-11-04 オンコホスト リミテッド IL-31 Improves Efficacy of Macrophage-Based Adoptive Cell Therapy for Cancer
CN110872354B (en) * 2018-09-04 2022-11-01 华瑞同康生物技术（深圳）有限公司 Chicken-derived monoclonal antibody and single-chain antibody of mammal cell recombinant anti-human TK1, and preparation method and application thereof
JP6935383B2 (en) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 Immunodeficient mouse
CN109266618B (en) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 Macrophage capable of targeting tumor cells and preparation method thereof
US20220169746A1 (en) * 2019-02-26 2022-06-02 The University Of Vermont And State Agricultural College Antibodies to neoantigens and uses thereof
WO2020223550A1 (en) * 2019-04-30 2020-11-05 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
BR112022003970A2 (en) 2019-09-03 2022-06-21 Myeloid Therapeutics Inc Methods and compositions for genomic integration
WO2021119538A1 (en) * 2019-12-11 2021-06-17 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods for manufacture and uses thereof
BR112022024228A2 (en) 2020-06-04 2023-02-07 Carisma Therapeutics Inc CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS
CN111925448B (en) * 2020-08-03 2022-06-21 山东大学 Preparation method of in vivo-generated CAR-macrophage and application of in vivo-generated CAR-macrophage in tumor immunotherapy
EP4240367A2 (en) 2020-11-04 2023-09-13 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2022186625A1 (en) * 2021-03-03 2022-09-09 서울대학교산학협력단 Method for producing chimeric antigen receptor-macrophages and use of same cells
KR20220131801A (en) 2021-03-22 2022-09-29 주식회사 이뮤노로지컬디자이닝랩 Transformed professional antigen presenting cells specifically binding to antigen containing chimeric antigen receptor(CAR) and uses thereof
KR20220132401A (en) 2021-03-23 2022-09-30 주식회사 이뮤노로지컬디자이닝랩 Transformed professional antigen presenting cells specifically binding to antigen containing chimeric antigen receptor(CAR) and uses thereof
WO2022248602A1 (en) * 2021-05-25 2022-12-01 Institut Curie Myeloid cells overexpressing bcl2
CN115011561A (en) * 2022-06-22 2022-09-06 深圳先进技术研究院 Chimeric antigen receptor macrophage and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065763A1 (en) * 2008-12-04 2010-06-10 Savoy Pharmaceuticals, Inc. Monoclonal antibodies to human thymidine kinase to treat cancer
WO2011082345A2 (en) * 2009-12-30 2011-07-07 Brigham Young University Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0785993B1 (en) 1993-08-06 2003-05-07 Brigham Young University Technology Transfer Office Monoclonal antibodies to thymidine kinase isozymes
US7311906B2 (en) 2004-04-30 2007-12-25 Brigham Young University Anti-viral activity of an anti-thymidine kinase monoclonal antibody
US7837998B2 (en) 2004-05-21 2010-11-23 Nathaniel Lallatin Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
CN104910279B (en) * 2015-06-05 2019-02-22 重庆精准生物技术有限公司 Target Chimeric antigen receptor, the Lentiviral and its preparation method and application of carcinomebryonic antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065763A1 (en) * 2008-12-04 2010-06-10 Savoy Pharmaceuticals, Inc. Monoclonal antibodies to human thymidine kinase to treat cancer
WO2011082345A2 (en) * 2009-12-30 2011-07-07 Brigham Young University Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARMEN S.M. YONG ET AL: "Using Electroporation to Determine Function of a Chimeric Antigen Receptor in T Cell and Macrophage Cell Lines", THE OPEN GENE THERAPEY JOURNAL, vol. 5, no. 1, 23 August 2013 (2013-08-23), pages 1 - 11, XP055332722, ISSN: 1875-0370, DOI: 10.2174/1875037020130715001 *
PAUL S ET AL: "Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single- chain variable region fragment", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, US, vol. 11, no. 10, 1 July 2000 (2000-07-01), pages 1417 - 1428, XP008154583, ISSN: 1043-0342, DOI: 10.1089/10430340050057495 *
PHILLIP K DARCY ET AL: "Manipulating immune cells for adoptive immunotherapy of cancer", CURRENT OPINION IN IMMUNOLOGY., vol. 27, 1 April 2014 (2014-04-01), GB, pages 46 - 52, XP055332723, ISSN: 0952-7915, DOI: 10.1016/j.coi.2014.01.008 *
ZHANG F ET AL: "A monoclonal antibody specific for human thymidine kinase 1", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 20, no. 1, 1 February 2001 (2001-02-01), pages 25 - 34, XP002517208, ISSN: 0272-457X, DOI: 10.1089/027245701300060382 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030938B2 (en) 2023-01-20 2024-07-09 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof

Also Published As

Publication number Publication date
CN108137704A (en) 2018-06-08
WO2017025944A2 (en) 2017-02-16
EP3334764A2 (en) 2018-06-20
KR20180054600A (en) 2018-05-24

Similar Documents

Publication Publication Date Title
WO2017025944A3 (en) Macrophage chimeric antigen receptor (moto-car) in imunotherapy
SG11202007532TA (en) Neural network accelerator
IL294146A (en) Anti-cmet antibody drug conjugates and methods for their use
IL274617A (en) Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
EP3661955A4 (en) Cytokine conjugates for the treatment of autoimmune diseases
IL276728A (en) Snap-rf interconnections
EP3494207A4 (en) Cancer modeling platforms and methods of using the same
WO2016086186A3 (en) Heterodimeric antibodies including binding to cd8
EP3661676C0 (en) Feedstocks for additive manufacturing, and methods of using the same
EP3697404A4 (en) Compositions and methods for broad-spectrum antiviral therapy
WO2018236870A3 (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
EP3813539A4 (en) Methods and devices for producing biodiesel, diesel-range hydrocarbons, and products obtained therefrom
EP3164157A4 (en) Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
EP3625154A4 (en) Adjustable conveyor belt guiderail and related methods
EP3880132A4 (en) Weight distribution exoskeleton
EP3518944A4 (en) Adaptive chimeric antigen receptor t-cell design
EP3915063C0 (en) Multi-model structures for classification and intent determination
EP3506943A4 (en) Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
EP3762386A4 (en) Adenosine receptor antagonists and uses thereof
EP3647146A4 (en) Traveling evaluation method and pseudo-emotion generation method
IL279309A (en) Anti-bcma car antibodies, conjugates, and methods of use
WO2014165644A3 (en) Combination treatments with sonic hedgehog inhibitors
EP3820522A4 (en) Methods for detecting and treating cancers having adenosine pathway activation
EP3448885A4 (en) Antibody conjugates and methods of making and using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16801306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2998406

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20187007097

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201890489

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 11201802046Y

Country of ref document: SG

Ref document number: 2016801306

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016305353

Country of ref document: AU

Date of ref document: 20161013

Kind code of ref document: A